Home · Peptide Library · Ozempic
Ozempic
Ozempic is the FDA-approved type 2 diabetes drug from Novo Nordisk. It's a once-weekly injection of semaglutide, the same active ingredient in Wegovy, approved specifically for blood sugar control and heart protection in diabetes.
- Active ingredient
- Semaglutide
- Prescribed dose
- 0.25–2 mg weekly (titrated)
- Manufacturer
- Novo Nordisk
- FDA approved
- 2017 · Type 2 diabetes
Dosing requires prescription and clinical supervision. Talk to your healthcare provider about whether Ozempic is right for you.
Quick Answer
Ozempic is FDA-approved for type 2 diabetes. People on it typically drop their A1c by about 1.5 points. If your A1c is 8.5, that's a drop to around 7. It's the same drug as Wegovy at a lower dose, approved for diabetes instead of weight management. The doses are semaglutide 0.5mg, 1mg, or 2mg weekly. A 2016 cardiovascular trial also showed Ozempic cut major heart events by 26% in adults with diabetes and high heart risk. Below: what the trials actually show, how it compares to Mounjaro, and the side effects worth knowing.
What is Ozempic?
Ozempic is the brand-name version of semaglutide made by Novo Nordisk for type 2 diabetes. The FDA approved it in 2017. It's prescribed for adults with type 2 diabetes whose blood sugar isn't controlled by diet, exercise, and metformin alone. Ozempic is the same active ingredient as Wegovy, just at a lower dose for a different reason. Ozempic treats diabetes. Wegovy treats obesity. The same molecule is also sold as Rybelsus in pill form.
How it works
Ozempic works by mimicking a hormone your gut already makes when you eat. The hormone is called GLP-1, and it does three things at once. It tells your pancreas to release insulin when blood sugar rises. It tells your brain you're full. And it slows down how fast food leaves your stomach. Ozempic is a long-lasting copy of GLP-1. It activates the same receptor more strongly than your body's own GLP-1. And it stays in your system for about a week per dose. The result for someone with type 2 diabetes: steadier blood sugar, less appetite, and modest weight loss as a side benefit.
How Ozempic compares
Ozempic vs Wegovy
Same drug, different dose, different FDA approval. Here's what that actually means for you.
Ozempic and Wegovy are the same drug. That drug is semaglutide, made by Novo Nordisk. The difference is the dose and what each is FDA-approved for. Ozempic is approved for type 2 diabetes at 0.5mg, 1mg, or 2mg weekly. Wegovy is approved for chronic weight management at the higher 2.4mg weekly dose. What this means for you. If you have type 2 diabetes and you're trying to manage blood sugar, Ozempic is the standard. If you don't have diabetes and your goal is weight loss, Wegovy is the FDA-approved choice. Both lower blood sugar. Both reduce appetite. Wegovy produces more weight loss in trials because the dose is higher. Ozempic still produces meaningful weight loss as a side benefit, typically 6 to 14 pounds at the higher 2mg dose.
Ozempic vs Mounjaro
The two FDA-approved type 2 diabetes brands. Here's where each wins.
Ozempic and Mounjaro are both FDA-approved for type 2 diabetes. Mounjaro produces more A1c reduction. In a 2021 head-to-head trial, people on Mounjaro dropped their A1c by about 2.3 points at 40 weeks. People on Ozempic dropped about 1.9 points. Mounjaro also produced more weight loss as a side benefit, about 25 pounds versus 14 pounds at 200-pound baseline. Why the gap? Ozempic mimics one of your body's natural fullness signals: GLP-1. Mounjaro mimics two at once: GLP-1 plus GIP. The second signal adds extra appetite suppression and improves how your body handles sugar. What Ozempic still wins on. The deepest cardiovascular evidence in the diabetes population. SUSTAIN-6 enrolled 3,297 adults with type 2 diabetes and high heart risk. Ozempic cut their major heart events by 26% over about two years. Mounjaro's cardiovascular outcomes trial is still running. Until that data lands, Ozempic is the option with proven heart protection in the diabetes population. What this means for you. If you need maximum A1c reduction, Mounjaro is the stronger choice. If you have diabetes and existing heart disease, Ozempic is the option with proven cardiovascular benefit today.
Approval status
Ozempic got FDA approval in 2017 for type 2 diabetes. The SUSTAIN trial program established efficacy across multiple groups. SUSTAIN-1 covered drug-naive patients. SUSTAIN-2 through 5 covered patients on background diabetes therapies. SUSTAIN-7 was the head-to-head against dulaglutide. SUSTAIN-6 was the cardiovascular outcomes trial. It enrolled 3,297 adults with type 2 diabetes and high heart risk. Ozempic cut their major heart events by 26% over about two years. The FDA expanded the label in 2020 to include cardiovascular risk reduction in adults with type 2 diabetes and established heart disease.
Who should not take Ozempic
This page is informational only. Whether Ozempic is appropriate for you depends on your full medical history, current medications, and personal risk factors. Discuss with your healthcare provider for a personalized assessment.
Emerging safety evidence
Bone mineral density emerged as a consideration in a 2026 head-to-head retrospective (Liu et al., J Clin Endocrinol Metab). The study followed 255 GLP-1 RA users against 255 matched controls over 17 months. In people with diabetes, which is Ozempic's main population, bone density loss was similar between the GLP-1 group and matched controls. The diabetes-specific bone story stayed quiet. In people without diabetes (off-label Ozempic territory), the GLP-1 group lost modestly more bone at the total hip, -1.0% versus -0.6% in controls. Within the GLP-1 group, bone loss correlated with weight loss. That suggests the effect is weight-loss-mediated rather than a direct drug action. The pattern matches what's seen with bariatric surgery and severe caloric restriction. Fracture-outcome data is still maturing. We don't know yet whether the bone-density signal becomes a fracture problem. Particularly relevant if you're at baseline fracture risk: post-menopausal, older adult, prior osteopenia, or prior osteoporosis.
Common questions
Is Ozempic the same as Wegovy?
Same drug, different dose, different FDA approval. Both are semaglutide made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes at doses up to 2mg per week. Wegovy is FDA-approved for chronic weight management at the higher 2.4mg dose. If you have diabetes, Ozempic is the standard. If you don't have diabetes and want to lose weight, only Wegovy is FDA-approved for that purpose.
How much does Ozempic lower A1c?
About 1.5 points on average over six months in the FDA-approval trials. If your A1c is 8.5, that's a drop to around 7. About 70% of people on the 1mg dose got below 7%. The 2mg dose drops A1c a bit further, about 1.7 to 2.1 points. Real-world results vary based on your starting A1c, your diet, your other diabetes medications, and how consistently you take it.
How much weight do you lose on Ozempic?
About 6 to 14 pounds in the FDA-approval trials over 30 to 40 weeks, depending on the dose. Less than Wegovy because the dose is lower. The 2mg dose, the highest approved for diabetes, gets closer to 14 pounds. Most weight loss happens in the first 6 months. Discontinuation reverses about two-thirds of the loss within a year if you stop the drug.
What are the side effects of Ozempic?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation. They tend to be worst at dose escalation and ease over a few weeks. Less common but serious: gallbladder disease, pancreatitis. Hypoglycemia is rare with Ozempic alone but can happen if you're also on insulin or sulfonylureas. A 2026 retrospective also showed modest extra bone-density loss in adults without diabetes who lost weight on a GLP-1. Fracture-outcome data isn't there yet.
Does Ozempic reduce heart attack risk?
Yes, in adults with type 2 diabetes and high heart risk. The SUSTAIN-6 trial enrolled 3,297 adults with type 2 diabetes plus established heart disease or high cardiovascular risk factors. People on Ozempic had 26% fewer major heart events over about two years compared to placebo. The FDA expanded the label in 2020 to include cardiovascular risk reduction in this population. The benefit is strongest if you already have heart disease. For diabetes alone without heart risk, the cardiovascular protection is less established.
What other GLP-1 options exist besides Ozempic?
Wegovy is the same molecule (semaglutide) at a higher dose, approved for weight management. Mounjaro (tirzepatide) is a dual-receptor GLP-1 that lowered A1c more than Ozempic in head-to-head trials. Victoza (liraglutide) is a daily injection. Each drug targets either diabetes, weight loss, or both depending on the brand label.
Full research profile
The full semaglutide research profile covers the complete SUSTAIN trial program, SELECT cardiovascular data, FLOW kidney outcomes, mechanism of action, and comparison with tirzepatide and other GLP-1 agents.
Ozempic and Wegovy share the same active ingredient: semaglutide. The full PSI semaglutide page covers the diabetes trial data side by side with the weight-loss data. It also covers the SUSTAIN-6 and SELECT cardiovascular outcomes in detail, the kidney-protection findings from FLOW, and how the evidence compares against tirzepatide.
View full Semaglutide research profile →Comparisons
Related brands
Related research
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.